1. Home
  2. STTK vs CNNE Comparison

STTK vs CNNE Comparison

Compare STTK & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.95

Market Cap

459.4M

Sector

Health Care

ML Signal

HOLD

CNNE

Cannae Holdings Inc.

HOLD

Current Price

$12.48

Market Cap

497.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
CNNE
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
459.4M
497.5M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
STTK
CNNE
Price
$6.95
$12.48
Analyst Decision
Buy
Buy
Analyst Count
6
3
Target Price
$7.60
$21.33
AVG Volume (30 Days)
502.9K
692.7K
Earning Date
04-30-2026
05-11-2026
Dividend Yield
N/A
4.81%
EPS Growth
53.02
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
$499,700,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.37
52 Week Low
$0.71
$10.46
52 Week High
$7.68
$21.96

Technical Indicators

Market Signals
Indicator
STTK
CNNE
Relative Strength Index (RSI) 65.29 58.74
Support Level $5.75 $11.54
Resistance Level N/A $16.41
Average True Range (ATR) 0.47 0.45
MACD 0.03 0.24
Stochastic Oscillator 61.66 85.84

Price Performance

Historical Comparison
STTK
CNNE

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About CNNE Cannae Holdings Inc.

Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.

Share on Social Networks: